Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.

MLA

Nowakowski, Grzegorz S., et al. “Safety and Efficacy of Durvalumab with R-CHOP or R2-CHOP in Untreated, High-Risk DLBCL: A Phase 2, Open-Label Trial.” International Journal of Hematology, vol. 115, no. 2, Feb. 2022, pp. 222–32. EBSCOhost, https://doi.org/10.1007/s12185-021-03241-4.

APA

Nowakowski, G. S., Willenbacher, W., Greil, R., Larsen, T. S., Patel, K., Jäger, U., Manges, R. F., Trümper, L., Everaus, H., Kalakonda, N., Brown, P., Jørgensen, J. M., Cunningham, D., Dell’Aringa, J., Fox, B., Rubio, N. D., Kilavuz, N., Casadebaig, M.-L., Manzke, O., & Munoz, J. (2022). Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. International Journal of Hematology, 115(2), 222–232. https://doi.org/10.1007/s12185-021-03241-4

Chicago

Nowakowski, Grzegorz S., Wolfgang Willenbacher, Richard Greil, Thomas S. Larsen, Krish Patel, Ulrich Jäger, Robert F. Manges, et al. 2022. “Safety and Efficacy of Durvalumab with R-CHOP or R2-CHOP in Untreated, High-Risk DLBCL: A Phase 2, Open-Label Trial.” International Journal of Hematology 115 (2): 222–32. doi:10.1007/s12185-021-03241-4.